UK GPs oppose abolition of prescription charges

14 April 2010

Almost two-thirds of general practitioners in the UK are against the abolition of prescription charges for all patients under the National Health Service, a GP newspaper survey has found. However, leaders of the British Medical Association (BMA) have repeatedly called for prescription charges to be abolished across the UK.

The survey of 1,266 GPs for GP newspaper found that 63% of doctors do not support such a change. Just 32% do, while 4% remain unsure about the issue. GPs suggested that providing free prescriptions to all patients would be unaffordable. Many argued that well-off patients should not qualify for free prescriptions, even if they had long-term conditions.

'Patients should bear part of the cost of any medication or treatment, so they understand that these things are not free,' one said. GPs are split on whether prescription charges prevent people accessing health care.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical